🏛️ Verified NIH Record • Updated 2026-08-13
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis (NCT07290569)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Oruka Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (6 items).
Location: Oruka Therapeutics Investigative Site — Phoenix, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (36 Sites)
- Oruka Therapeutics Investigative Site — Phoenix, Arizona
- Oruka Therapeutics Investigative Site — North Little Rock, Arkansas
- Oruka Therapeutics Investigative Site — Los Angeles, California
- Oruka Therapeutics Investigative Site — Los Angeles, California
- Oruka Therapeutics Investigative Site — San Diego, California
- Oruka Therapeutics Investigative Site — Miami, Florida
- Oruka Therapeutics Investigative Site — Rolling Meadows, Illinois
- Oruka Therapeutics Investigative Site — Plainfield, Indiana
- Oruka Therapeutics Investigative Site — Rockville, Maryland
- Oruka Therapeutics Investigative Site — Kew Gardens, New York
- Oruka Therapeutics Investigative Site — Chapel Hill, North Carolina
- Oruka Therapeutics Investigative Site — Cleveland, Ohio
- Oruka Therapeutics Investigative Site — Mason, Ohio
- Oruka Therapeutics Investigative Site — Portland, Oregon
- Oruka Therapeutics Investigative Site — Portland, Oregon
- Oruka Therapeutics Investigative Site — Philadelphia, Pennsylvania
- Oruka Therapeutics Investigative Site — Frisco, Texas
- Oruka Therapeutics Investigative Site — Houston, Texas
- Oruka Therapeutics Investigative Site — Webster, Texas
- Oruka Therapeutics Investigative Site — Norfolk, Virginia
- Oruka Therapeutics Investigative Site — Surrey, British Columbia
- Oruka Therapeutics Investigative Site — Surrey, British Columbia
- Oruka Therapeutics Investigative Site — Fredericton, New Brunswick
- Oruka Therapeutics Investigative Site — Ajax, Ontario
- Oruka Therapeutics Investigative Site — Markham, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.